Introduction {#s1}
============

Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (*IDH1*) and *IDH2* genes, which catalyze the production of α-ketoglutarate (α-KG) from isocitrate, have been associated with numerous forms of cancer ([@bib9]) leading to exploration of how changes in their function could be linked to the development of tumors. All known mutations alter key residues in both proteins that decrease the enzyme's affinity for isocitrate, leading to the theory that the loss of IDH function perturbs the equilibrium of α-KG, negatively affecting various α-KG dependent enzymes ([@bib18]). However, work from the Thompson group determined that the tumor-associated mutations actually created a neomorphic function; rather than catalyzing the production of α-KG, mutant IDH proteins produce the oncometabolite 2-hydroxyglutarate (2-HG) ([@bib14]). Dang and colleagues first described this neomorphic function and demonstrated a correlation between 2-HG levels and glioma samples harboring *IDH* mutations ([@bib2]). In their 2010 Cancer Cell paper, Ward and colleagues further confirm these findings and extend the association of 2-HG levels and *IDH* mutations to acute myeloid leukemia (AML) ([@bib16]).

In Figure 2, Ward and colleagues transfected 293T cells with either wild type or mutant forms of *IDH2*. They assessed cell lysates for their ability to generate NDPH in the presence of isocitrate (Figure 2A) or to consume NADPH in the presence of α-KG (Figure 2B). Their data indicated that cells transfected with IDH2^WT^ generated NADPH in the presence of isocitrate, and did not consume much NADPH in the presence of α-KG, consistent with its canonical function of converting isocitrate to α-KG. However, IDH2^R172K^ displayed the opposite effect, indicating that it was able to consume NADPH in an α-KG dependent manner. These data were the first suggesting that the mutant form of IDH2 might have a neomorphic function. This key experiment will be replicated in Protocol 1.

In Figure 3, Ward and colleagues use gas-chromatography mass spectrometry (GC-MS) to identify a novel function of IDH2^R172K^. They identified a unique peak in the lysates of cells transfected with IDH2^R172K^ that corresponded to the retention time of the metabolite 2-hydroxyglutarate (2-HG). They confirmed the metabolite identity by mass spectrometry. These data provide evidence that the mutant form of IDH2 leads to 2-HG production. This key experiment will be replicated in Protocol 2.

In Figure 5, Ward and colleagues examined the correlation between AML patient samples carrying *IDH* mutations and the levels of 2-HG found in those samples. They showed that patient samples carrying *IDH* mutations contained higher levels of 2-HG than samples from patients with WT *IDH* genes. This key experiment will be replicated in Protocol 3.

Several groups' work has supported the results of Ward and colleagues, who themselves confirmed and extended their initial findings in subsequent reports ([@bib14]; [@bib15]). Leonardi and colleagues confirmed that mutant forms of *IDH*, specifically *IDH1*, did not perform the canonical forward reaction converting isocitrate to α-KG ([@bib10]). Using magnetic resonance spectroscopy, Izquierdo-Garcia and colleagues confirmed that transfection of cells with mutant *IDH* forms increased the levels of 2-HG ([@bib6]), while Jin and colleagues demonstrated similar findings for *IDH1* and *IDH2* mutants ([@bib7]). Evaluating 2-HG levels in astrocytomas and gliomas harboring various *IDH1* mutations, Pusch and colleagues also showed that any mutations in *IDH1* correlated with increased levels of 2-HG in human patient samples ([@bib12]), a trend also observed by Juratli and colleagues ([@bib8]).

Discovery of IDH neomorphic function, resulting in the production of the \'oncometabolite\' 2-HG, opened many avenues of research into how the production of excess 2-HG could impact tumorigenesis. Figueroa and colleagues expanded upon the foundation laid by Ward and colleagues and determined that excess 2-HG was correlated with changes in global methylation patterns ([@bib5]). Xu and colleagues showed that 2-HG was able to competitively inhibit many α-KG dependent enzymes, including several histone demethylases, and that exogenous 1-HG was able to inhibit histone demethylation ([@bib17]). Lu and colleagues also observed this correlation between 2-HG levels and perturbations in global histone methylation patterns, and went on to show that this resulted in impaired cellular differentiation ([@bib11]).

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors.

Protocol 1: Assessing the α-ketoglutarate dependent NADPH consumption of wild-type or mutant IDH2 {#s2-1}
-------------------------------------------------------------------------------------------------

In this protocol, 293T cells are transfected with empty vector, IDH2^WT^, or IDH2^R172K^. Lysates are generated from these cells and their ability to produce NADPH from NADP+ and isocitrate is assayed (Figure 2A). The same lysates are also assayed for their ability to consume NADPH in the presence of 0.5 mM α-ketoglutarate (α-KG) (Figure 2B). Expression of the transfected protein will be confirmed by Western blot (Figure 2C).

### Sampling {#s2-1-1}

Oxidative and reductive activity (Figures 2A and B):

-   Experiment has three conditions. Each will be performed with seven biological replicates and three technical replicates of each condition at each time point for a final power of at least 80%.Condition 1: 293T cells expressing *IDH2^WT^*Condition 2: 293T cells expressing *IDH2^R172K^*Condition 3: 293T cells expressing empty pCDNA3 vectoro Each lysate will be assessed for cell's ability to reduce NADP^+^ and oxidate NADPHo See Power Calculations section for details.

Confirmatory Western Blot (Figure 2C)

-   This is a quality control experiment and is not being powered to detect a specific effect size. Western blots will be performed alongside each biological replicate.

-   Western blotting of each lysate will be performed for the following proteinsIDH2IDH1Actin \[additional\]

### Materials and reagents {#s2-1-2}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                        Type                 Manufacturer                  Catalog \#                                   Comments
  ------------------------------ -------------------- ----------------------------- -------------------------------------------- -----------------------------
  293T cells                     Cells                ATCC                          CRL-3216                                     Original source unspecified

  Dulbecco's modified\           Media                Invitrogen                    11965118                                     Original unspecified
  Eagle's medium (DMEM)                                                                                                          

  FBS                            Reagent              Hyclone                       SH30071.03                                   Replaces FBS from CellGro

  IDH2^WT^ ORF in pCMV6          Plasmid              Origene                       RC201152                                     

  IDH2^R172K^ ORF in pCMV6       Plasmid              Origene                       RC400103                                     

  pCDNA3                         Plasmid              Invitrogen                    V790-20                                      

  Lipofectamine 2000             Reagent              Invitrogen                    11668027                                     

  M-Per Mammalian protein\       Reagent              Pierce                        78503                                        
  extraction reagent                                                                                                             

  Aprotinin                      Reagent              Sigma                         248614                                       Original protease\
                                                                                                                                 inhibitor cocktail\
                                                                                                                                 unspecified

  AEBSF                          Reagent              EMD Millipore                 101500-100MG                                 

  Leupeptin                      Reagent              Sigma                         L2884-100mg                                  

  Pepstatin A                    Reagent              EMD Millipore                 516481-100MG                                 

  NaOV                           Reagent              Sigma                         450243-50G                                   Original unspecified

  NaF                            Reagent              Sigma                         215309-50G                                   

  Sonicator                      Equipment            VCR                           75HT                                         Original unspecified

  Refrigerated\                  Equipment            Labnet International, Inc     PrismR                                       Original unspecified
  microcentrifuge                                                                                                                

  Tris-HCl                       Reagent              BioRad                        BR0011                                       Original unspecified

  MnCl2                          Reagent              M87-100                       Fisher                                       Original unspecified

  EDTA                           Reagent              VWR                           EM-4050                                      Original unspecified

  ß-NADP+                        Reagent              MP Biomedicals                ICN10116680                                  Original unspecified

  ß-NADPH                        Reagent              Sigma                         10107824001                                  Original unspecified

  D-(+)-threo-isocitrate         Reagent              Sigma                         I1252                                        

  Spectrophotometer              Instrument           Molecular Devices             Filter Max F5 Multi-mode Microplate Reader   Original unspecified

  6-well tissue\                 Materials            E& K Scientific               27160                                        Original unspecified
  culture plates                                                                                                                 

  96 well plates                 Materials            Fisher (Costar)               07-200-656                                   Original unspecified

  Tric-HCl                       Reagent              BioRad                        BR0011                                       Original unspecified

  Glycerol                       Reagent              VWR                           EM-4760                                      Original unspecified

  ß-mercaptoethanol              Reagent              Sigma                         M6250-250mL                                  Original unspecified

  Sodium dodecyl sulfate (SDS)   Reagent              Sigma                         L3771-100G                                   Original unspecified

  Bromophenol blue               Reagent              Sigma                         B0126-25G                                    Original unspecified

  Protogel                       Reagent              Fisher/National Diagnostics   50-899-90119                                 Original unspecified

  APS                            Reagent              Sigma                         248614                                       Original unspecified

  TEMED                          Reagent              Fisher                        BP150-100                                    Original unspecified

  nitrocellulose                 Materials            BioRad                        162-0112                                     Original unspecified

  Anti-IDH2 antibody\            Primary Antibody     Abcam                         ab55271                                      
  (mouse monoclonal)                                                                                                             

  Anti-IDH1 antibody\            Primary Antibody     Santa Cruz                    sc49996                                      
  (goat polyclonal)                                                                                                              

  Anti-Actin antibody\           Primary Antibody     Cell Signaling                12620                                        Not included in original.
  (rabbit monoclonal)-\                                                                                                          
  HRP conjugated                                                                                                                 

  ECL Mouse IgG,\                Secondary Antibody   GE Healthcare                 NA931V                                       
  HRP-linked whole Ab\                                                                                                           
  (from sheep)                                                                                                                   

  HRP conjugated rabbit\         Secondary Antibody   Invitrogen                    811620                                       Original unspecified
  anti-goat antibody                                                                                                             

  Protein ladders                Reagent              Cell Signaling Tech.          7727L                                        Original unspecified

  Gold Biotech                   p007-1500            Original unspecified                                                       

  ECL reagent                    Reagent              Fisher Scientific             PI34096                                      Original unspecified

  Endo-free maxiprep kit         Reagent              Qiagen                        12362                                        Original unspecified

  α-ketoglutarate                Reagent              Sigma                         75892-25G                                    Original unspecified

  DC Protein Assay Kit           Kit                  BioRad                        5000112                                      Original unspecified

  Alpha innotech imager          Equipment            Alpha Innotech                Alphaimager 2200                             

  sodium azide                   Reagent              Sigma                         S2002-5G                                     Original Unspecified

  Ponceau stain                  Reagent              Quality Biological            50-751-6798                                  Additional reagent
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-1-3}

#### Notes {#s7}

-   293T cells are grown in DMEM supplemented with 10% FBS at 37°C in 5% CO~2~

-   Cells will be sent for STR profiling and mycoplasma testing.

1.  Confirm insert identity by sequencing.Origene clones are shipped with two sequencing primers.

2.  Sub-clone IDH2^WT^ and IDH2^R172K^ from the Origene pCMV6-Entry vectors into pcDNA3.Confirm insert identity by sequencing.Confirm vector integrity by agarose gel electrophoresis.

3.  Grow up and use an endo-free maxiprep kit to prep the following vectors:pcDNA3pcDNA3-IDH2^WT^pcDNA3-IDH2^R172K^

4.  Seed 0.25-1x10^6^ 293T cells per well of a 6-well plate in growth medium without antibiotics.Grow overnight.Confirm cells at 70--80% confluency by light microscopy at time of transfection.

5.  Transfect 293T cells with pcDNA3, pcDNA3-IDH2^WT^, pcDNA3-IDH2^R172K^ with Lipofectamine 2000 according to manufacturer instructions for a 6-well plate.As per manufacture's instructions 1 µg plasmid DNA per well in a 6-well plate for 70--80% confluent 293T cells.Transfect 1 well (or plate if reaction needs to be scaled up) for each constructThis will be one biological replicate

6.  48 hr after transfection, remove medium from cells, wash with PBS, and lyse in 1 ml/well of mammalian protein extraction reagent containing protease inhibitor cocktail (aprotinin, AEBSF, leupeptin and pepstatin A, all at 1:1000) and phosphatase inhibitor cocktails (NaOV, Pepstatin A, Leupeptin, AEBSF, NaF, aprotinin) at 4°C or on ice.

7.  Collect lysate and sonicate.Perform test for optimal conditions as follows.Sonication for 5 minSonication for 10 minCentrifuge lysate in refrigerated microcentrifuge at 14000x*g* at 4°C for 10 min.Collect supernatants and measure the protein concentration of each using the DC Protein Assay Kit II according to the manufacturer's instructions.Will need \>50 µg total protein to proceedIf 50 µg total protein is not achieved the reaction will be scaled to a 25 cm plate. These conditions will be used for the subsequent replicates without any further optimization.If further optimization is needed, the experiment will not proceed to step 7 until this is achieved.Aliquot lysate protein for measuring IDH oxidative (Step 9) and reductive activity (step 10) and for examining expression of IDH2^WT^, IDH2^R172K^ by western blot (step 11).

8.  Measuring IDH oxidative activity:Mix 0.3 µg of each protein lysate with 200 µl of assay buffer solution in a 96-well plate. Each condition should be plated in triplicate.Assay buffer solution: 100 mM Tris-HCl buffer (pH 7.5), 1.3 mM MnCl~2~, 0.33 mM EDTA, 0.1 mM ß-NADP^+^, 0.1 mM D-(+)-*threo*-isocitrateInclude buffer lacking lysate protein to determine background reading.Put mixtures in spectrometer and measure absorbance at 340 nm every 20 s for 30 min.Use absorbance readings at 5 min intervals for analysis.An exploratory investigation of all data will be used in the analysis as well.

9.  Measuring IDH reductive activity:Mix 3 µg of each protein lysate with 200 µl of assay buffer solution in a 96-well plate. Each condition should be plated in triplicate.Assay buffer solution: 100 mM Tris-HCl buffer (ph 7.5), 1.3 mM MnCl~2~, 0.01 mM ß-NADPH, 0.5 mM α-ketoglutarateInclude buffer lacking lysate protein to determine background reading.Put mixtures in spectrometer and measure absorbance at 340 nm every 20 min for 3 hr.

10. Western blot to confirm protein expression:Add sample buffer and boil lysates to prepare for loading.Sample buffer: 0.5 mL 1 M TrisCl, pH 6.8, 1 mL glycerol, 0.5 mL ß-mercaptoethanol, 0.24 g SDS, 0.1 mL 1% bromophenol blue.Add 30 µg of protein per well by diluting protein to same concentrations (based on protein quantification results) in 10 µL of lyse buffer and added 20 µL of sample bufferPlace at 65˚C for 15 min.Separate 20--30 µg of protein per lane on an 8% SDS-PAGE gel with protein ladder.Run through the stacker at 45 mAmp/gel, then increase to 300 V for 3 hr.Transfer to nitrocellulose membrane.Transfer at 100 A for 1 hr 40 min in 2.5 mM Tris, 19 mM glycine in 20% methanol.Wash membrane in deionized water then wash in 1X TBST.Confirm protein transfer with Ponceau stain.Block membrane with 5% milk/0.2% azide in TBST for 30 min at room temperature.Incubate with the following primary antibodies using the manufacturer's recommended dilution. Following antibodies will be probed at one timeMouse anti-IDH2; 37 kDaGoat anti-IDH1; 47 kDaIncubate with appropriate secondary antibodies using manufacture's recommended dilutionsHRP-conjugated sheep anti-mouseHRP-conjugated rabbit anti-goatThe anti-actin antibody is HRP conjugated and a secondary antibody incubation is not necessary.Treat membranes with ECL reagent according to manufacturer's recommendations and image.Between antibody incubations, inactivate HRP activity by incubating with a final concentration of 1mM sodium azide in blocking buffer.Shake at room temp for 1 hr.Wash membrane 3 x 5 min in 1X TBST.Incubate with ECL reagent as directed by the manufacturer and image at a time point of at least 5 min to confirm HRP inactivationSave blank imageIncubate with Rabbit anti-actin-HRP; 45 kDa \[additional\] to evaluate loading controlTreat membranes with ECL reagent according to manufacturer's recommendations and image.

11. Repeat steps 6--9 independently six additional times.

### Deliverables {#s2-1-4}

-   Data to be collected:Sequencing reads and agarose gel images confirming vector identity and integritypcDNA3pcDNA3-IDH2^WT^pcDNA3-IDH2^R172K^Raw data from plate reader for reduced NADP^+^ and oxidated NADPHBackground subtracted readingsFull western images, including ladderPonceau stains confirming protein transferECL negative control from step 9-hr

### Confirmatory analysis plan {#s2-1-5}

Statistical Analysis of the Replication Data:

-   Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.For oxidative activity assays:Bonferroni corrected ANOVA followed by two-tailed Bonferroni corrected planned contrasts:Vector vs. IDH2^WT^Vector vs. IDH2^R172K^For reductive activity assaysBonferroni corrected ANOVA followed by two-tailed Bonferroni corrected planned contrasts:Vector vs. IDH2^WT^Vector vs. IDH2^R172K^Western blot:This is a quality control experiment and is not powered to detect a specific effect.

-   Meta-analysis of original and replication attempt:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-1-6}

Although not performed by the original authors, actin was added as internal loading control for Western blots and will be added to the resulting data. Details of the Western blot protocol and possible stripping/sodium azide treatment were unspecified; information was added by the replicating lab. The details of the transfection specifics were unspecified and that information is provided by the replicating lab. Additionally, these experiments will be conducted in 6-well dishes, however, if total protein yield is not sufficient, the replicating lab will scale up to 25 cm dishes.

### Provisions for quality control {#s2-1-7}

All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/8l4ea/>).

-   STR profiling and mycoplasma testing results

-   Sequencing reads and agarose gel images confirming vector identity and integrity

-   Ponceau stains confirming protein transfer for Western Blot

-   Confirmation of HRP inactivation prior to proceeding with the following antibodies.

Protocol 2: Production of 2-HG from IDH2 WT and mutant transfected cells {#s2-2}
------------------------------------------------------------------------

In this protocol, the production of 2-HG from 293T cells transfected with vectors expressing IDH2^WT^ or IDH2^R172K^ is measured by gas chromatography-mass spectrometry (as seen in Figures 3A--C). The amount of 2-HG relative to glutamate is quantified, as seen in Figure 3D.

### Sampling {#s2-2-1}

-   Experiment will be performed with at least three biological replicates for a final power of at least 80%. The original data are qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.See Power Calculations section for details.

-   Experiment has three conditions:Condition 1:293T cells expressing IDH2^WT^Condition 2: 293T cells expressing IDH2^R172K^Condition 3: 293T cells expressing empty pCDNA3 vector

-   For each condition, lysates will be analyzed for 2-HG/glutamate levels

### Materials and reagents {#s2-2-2}

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                               Type         Manufacturer                Catalog \#             Comments
  ------------------------------------- ------------ --------------------------- ---------------------- -------------------------------------------
  293T cells                            Cells        ATCC                        CRL-3216               Original source unspecified

  Dulbecco's modified\                  Media        Invitrogen                  11965118               Original unspecified
  Eagle's medium (DMEM)                                                                                 

  Pen/Strep                             Reagent      Fisher                      15140-122              Original unspecified

  FBS                                   Reagent      Hyclone                     SH30071.03             Replaces FBS from CellGro

  pcDNA-IDH2^WT^                        Plasmid      Generated in\                                      
                                                     Protocol 1                                         

  pcDNA-IDH2^R172K^                     Plasmid      Generated in\                                      
                                                     Protocol 1                                         

  Lipofectamine 2000                    Reagent      Invitrogen                  11668027               

  Methanol                              Reagent      Fisher                      A452SK-4               Original unspecified

  Refrigerated centrifuge               Equipment    Labnet International, Inc   PrismR                 Original unspecified

  Nitrogen gas                          Reagent      Generated in lab            Original unspecified   

  AG-1 X8 100-200\                      Reagent      Bio-Rad                     731-6211               Poly-Prep Columns, AG 1-X8, chloride form
  anion exchange column                                                                                 

  HCl                                   Reagent      Fisher                      SA56-1                 Original unspecified

  N-methyl-N-tert-\                     Reagent      Regis                       1-270243-200           
  butyldimethylsily\                                                                                    
  trifluoroacetamide (MTBSTFA; Regis)                                                                   

  Gas Chromatograph with\               Equipment    Agilent 7890A\                                     
  an HP-5MS capillary column\                        with 7693 Autosampler                              
  and Mass selective detector                                                                           

  Cold trap concentrator                Equiptment   Labconco Centrivap                                 

  R(-)-2-HG                             Reagent      Sigma-Aldrich               H8378-100MG            Original unspecified
  -------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-2-3}

#### Notes {#s16}

-   293T cells grown in DMEM supplemented with 10% FBS at 37°C in 5% CO~2~.

-   All cells will be sent for STR profiling and mycoplasma testing

1.  Seed 0.25--1 x 10^6^ 293T cells per well of a 6-well plate in growth medium without antibiotics.Grow overnight.Confirm cells at 70--80% confluence by light microscopy at time of transfection.

2.  Transfect 293T cells with pCDNA3, pCDNA3-IDH2^WT^, or pCDNA3-IDH2^R172K^ with Lipofectamine 2000 according to manufacturer instructions.Transfect 1 µg of plasmid DNA per well in 6-well plate at 70--80% confluence.Generate duplicate plates for each transfection:Harvest one plate at 24 hr.Harvest one plate at 48 hr.

3.  24 hr later, replace with fresh media with 1x pen/strep

4.  24 or 48 hr later, gently remove medium from proliferating cells.Note: from this point on this protocol contains information as described in ([@bib1]).

5.  Rapidly quench cells with 1--2 ml per well of -80°C methanol.Chill cells to -80°C and incubate at -80°C for 15 min.

6.  Scrape cells off the dish and transfer the cell suspension to a 15 ml conical tube.Centrifuge for 5 min at 2000x*g* at 4°C to pellet cellular debris.Transfer supernatant to a fresh 15 ml tube.

7.  Resuspend the pellet in 500 µl of -80°C 80% methanol in water by vortexing.Incubate at 4°C for 15 min.Centrifuge for 5 min at 2000x*g* at 4°C.Combine supernatant with supernatant from Step 6b.Repeat step 7 for a third round of extraction and combine all supernatants.

8.  Evaporate to dryness using a cold trap concentrator.

9.  Elute through an AG-1 X8 100--200 anion exchange resin according to the manufacturer's instructions.Wash with five column volumes of wash buffer.Elute in 3N HCl.

10. Evaporate to dryness using cold trap concentrator

11. Redissolve sample in MSTFA + FAME.Prepare 40 mg/mL Methoxyamine hydrochloride (MeOX) solution in pyridine.Weigh out methoxyamine hydrochloride in 1.5 ml Eppendorf tube on balance and add appropriate amount of pyridine.Vortex MeOX solution and sonicate at 60°C for 15 min to dissolve.Add 10 µl of 40 mg/ml MeOX solution to each dried sample.Shake at maximum speed at 60˚C for 1 hr.To 1 ml of MSTFA, add 10 µl of FAME marker.Vortex for 10 s.Add 91 µl of MSTFA + FAME mixture to each sample and standard. Cap immediately.Shake at maximum speed at 37°C.Transfer contents to glass vials with micro-inserts and cap immediately.Submit to GCTOF MS analysis.

12. Inject samples into GC-MS.Operate the detector in spitless mode using electron impact ionization.Ionizing voltage: -70 eVElectron multiplier: 1060 VGC temperature ramp:Hold at 100°C for 3 min.Ramp to 230°C at 4°C/min.Hold for 4 min.Ramp to 300°C.Hold for 5 min.Record mass range of 50--500 amu and record 2.71 scans/s.

13. Repeat steps 1--12 independently three additional times.

### Deliverables {#s2-2-4}

-   Data to be collected:24 hr samples:GC traces for all samples runClose-up of the time range showing metabolite abundance for aspartate, glutamate, and 2-HG for cells transfected with IDH2^WT^ (Figure 3A) and cells transfected with IDH2^R172K^ (Figure 3B).Mass spectrum confirmation of metabolite identity as 2-HG.48 hr runGC traces for all samples runClose-up of the time range showing metabolite abundance for aspartate, glutamate, and 2-HG for cells transfected with IDH2^WT^ (Figure 3A) and cells transfected with IDH2^R172K^ (Figure 3B).Quantification of the relative intensity of the 2-HG signal to the glutamate signal, graphed as seen in Figure 3D.

### Confirmatory analysis plan {#s2-2-5}

-   Statistical Analysis of the Replication Data:

-   Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric test.Two-way ANOVA performed on 2-HG/glutamate ratios followed by Fisher's LSD for the following comparisons:Vector vs. IDH2^WT^IDH2^WT^ vs. IDH2^R172K^o Analyses will be performed on both 24 and 48 hr runs.

-   Meta-analysis of original and replication attempt:The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the graph, as a single point on the same plot for comparison.

### Known differences from the original study {#s2-2-6}

-   The GC-MS sample preparation protocol was modified by the replicating lab including a shaking incubation step at 11f. However, this protocol was taken from Bennett et al. which the authors reference in the original manuscript.

### Provisions for quality control {#s2-2-7}

All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/8l4ea/>).

-   STR profiling and mycoplasma testing results.

-   Mass spectrum of the metabolite peak for derivatized 2HG to confirm identity.

Protocol 3: Assessing the correlation of IDH status with 2-HG levels in samples from patients with AML {#s2-3}
------------------------------------------------------------------------------------------------------

In this protocol, samples from patients with acute myeloid leukemia (AML) are examined for their IDH mutational status and their level of 2-HG, as seen in Figure 5.

### Sampling {#s2-3-1}

-   This experiment will use four samples per group for a final power of at least 80%.See Power Calculations section for details.

-   This experiment has three genetically distinct groups:AML patients with no *IDH* mutationsAML patients with mutant *IDH1*AML patients with mutant *IDH2,* including both R172K and R140Q mutants

-   All samples will come from Roswell Park Cancer Institute and are ficoll separated in media with 10% DMSO and prescreened for *IDH* genotypic status.

-   Each patient sample will be assessed for their ratio of 2-HG/glutamate.

### Materials and reagents {#s2-3-2}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                               Type             Manufacturer                Catalog \#     Comments
  ----------------------------------------------------- ---------------- --------------------------- -------------- -------------------------------------------
  Samples of peripheral blood, bone marrow,\            Patient sample   NA                          NA             Banked RPCI samples
  or pheresis from patients\                                                                                        
  with karyotypically normal AML                                                                                    

  DMSO                                                  Reagent          Fisher                      BP231-1        Original Unspecified

  Methanol                                              Reagent          Fisher                      A452SK-4       Original unspecified

  Refrigerated centrifuge                               Equipment        Labnet International, Inc   PrismR         Original unspecified

  AG-1 X8 100-200\                                      Reagent          Bio-Rad                     731-6211       Poly-Prep Columns, AG 1-X8, chloride form
  anion exchange column                                                                                             

  HCl                                                   Reagent          Fisher                      SA56-1         Original unspecified

  N-methyl-N-tert-\                                     Reagent          Regis                       1-270243-200   
  butyldimethylsily\                                                                                                
  trifluoroacetamide (MTBSTFA; Regis)                                                                               

  Gas Chromatograph with an\                            Equipment        Agilent 7890A with\                        
  HP-5MS capillary column and Mass selective detector                    7693 Autosampler                           

  Cold trap concentrator                                Equiptment       Labconco Centrivap                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-3-3}

1.  GC-MS analysis of 2-HG levels.If using frozen cells, warm cells to 37˚C in a 37˚C water bath for 10 minCentrifuge cells for 5 min at 1000x*g* to form a pelletIf necessary, transfer cells to a conical or microcentrifuge tubeGently remove freezing medium from MNCsProceed with metabolite extraction and GC-MS analysis as detailed in protocol 2 Steps 5 through 12.For each sample, divide the GC signal intensity of their 2-HG peak by the signal intensity of their glutamate peak and graph.

### Deliverables {#s2-3-4}

-   Data to be collected:Tabulated patient data (age, sex, *IDH* mutation status, 2-HG/glutamate ratio) (as seen in Table 1)GC traces for all samplesGraph of 2-HG/glutamate ratio for samples by mutational status, as seen in Figure 5C.

### Confirmatory analysis plan {#s2-3-5}

-   Statistical Analysis of the Replication Data:

-   Note: The authors report WT IDH ratios were less than 1% which we are using as the constant for the comparisons below.Bonferroni Correct one-sample t-test for 3 comparisons (alpha corrected for 2 test groups = 0.025)Constant vs. *IDH1^mutant^*Constant vs. *IDH2^mutant^*Constant vs *IDH1/2^mutants^*

-   Meta-analysis of original and replication attempt:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-3-6}

-   The GC-MS sample preparation protocol was modified by the replicating lab including a shaking incubation step at 11f, protocol 2. However, this protocol was taken from Bennett et al. which the authors reference in the original manuscript.

### Provisions for quality control {#s2-3-7}

All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/8l4ea/>). This includes confirmation of the GCMS peaks and elution times as well as MS QC data.

Power calculations {#s2-4}
------------------

For details of power calculations, see spreadsheet and additional files at <https://osf.io/9jkpg/>

### Protocol 1 {#s2-4-1}

Summary of original data estimated from graph reported in Figure 2A:

-   SD was calculated using formula SD = SEM\*(SQRT n=3).

  Sample        Time    Mean     SEM      SD
  ------------- ------- -------- -------- --------
  IDH2^WT^      0       0        0.0820   0.1421
  5             0.225   0.0820   0.1421   
  10            0.45    0.1025   0.1776   
  15            0.679   0.1538   0.2664   
  20            0.917   0.1974   0.3419   
  25            1.129   0.2512   0.4352   
  30            1.342   0.3      0.5196   
  IDH2^R172K^   0       0        0.0820   0.1421
  5             0.038   0.0820   0.1421   
  10            0.062   0.0820   0.1421   
  15            0.062   0.0820   0.1421   
  20            0.062   0.0820   0.1421   
  25            0.1     0.0820   0.1421   
  30            0.096   0.0820   0.1421   
  Vector        0       0        0.0564   0.0977
  5             0.021   0.0564   0.0977   
  10            0.021   0.0564   0.0977   
  15            0.017   0.0564   0.0977   
  20            0.017   0.0564   0.0977   
  25            0.033   0.0564   0.0977   
  30            0.021   0.0564   0.0977   

Linear regression to determine slopes from estimate values.

Calculations performed with R software (version 3.2.2) ([@bib13])

  Sample        Mean slope   SD      N
  ------------- ------------ ------- ---
  IDH2^WT^      0.01         0.090   3
  IDH2^R172K^   0.06         0.140   3
  Vector        0.67         0.280   3

Summary of original data estimated from graph reported in Figure 2B:

-   SD was calculated using formula SD = SEM\*(SQRT(n)), where n = 3.

  Sample        Time     Original_Value_Mean   SEM      SD
  ------------- -------- --------------------- -------- --------
  IDH2^WT^      0        0                     0.0039   0.0067
  17            -0.003   0.0060                0.0105   
  33            -0.004   0.0073                0.0126   
  50            -0.005   0.0102                0.0177   
  71            -0.006   0.0104                0.0181   
  90            -0.008   0.0114                0.0198   
  112           -0.009   0.0117                0.0202   
  131           -0.01    0.0075                0.0130   
  171           -0.014   0.0121                0.0211   
  IDH2^R172K^   0        0                     0.0039   0.0067
  17            -0.006   0.0039                0.0067   
  33            -0.009   0.0065                0.0114   
  50            -0.016   0.0085                0.0147   
  71            -0.024   0.0080                0.0139   
  90            -0.028   0.0087                0.0152   
  112           -0.036   0.0095                0.0164   
  131           -0.043   0.0104                0.0181   
  171           -0.055   0.0095                0.0164   
  Vector        0        0                     0.0026   0.0046
  17            0.001    0.0026                0.0046   
  33            0        0.0026                0.0046   
  50            0        0.0026                0.0046   
  71            0        0.0026                0.0046   
  90            0        0.0026                0.0046   
  112           -0.002   0.0026                0.0046   
  131           -0.002   0.0026                0.0046   
  171           -0.003   0.0026                0.0046   

Linear regression to determine slopes from estimates values.

Calculations performed with R software (version 3.2.2) ([@bib13])

  Sample        Mean slope   SD      N
  ------------- ------------ ------- ---
  IDH2^WT^      -0.0006      0.005   3
  IDH2^R172K^   -0.0241      0.013   3
  Vector        -0.0065      0.016   3

### Test family {#s2-4-2}

-   One-way ANOVA: Fixed effects, omnibus, one-way: Bonferroni correction: alpha error = 0.025.

### Power calculations {#s2-4-3}

-   Power calculations were performed using G\*Power, version 3.1.7 ([@bib4]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.2.2 ([@bib13]).

  -----------------------------------------------------------------------------------------------------------------
  Groups                   F test statistic   Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------ ------------------ -------------- ----------------- ---------------- -------------------
  Slopes of NADPH\         F(2,6) = 10.8      0.7826         1.897636          99.99%^1^        21^1^\
  production from\                                                                              (3 groups)
  IDH2^WT^, IDH2^R172^,\                                                                        
  or Vector (Figure 2A)                                                                         

  Slopes of NADP^+^\       F(2,6) = 3.02      0.5023         1.0048            94.13%^1^        21^1^ (3 groups)
  production from\                                                                              
  IDH2^WT^, IDH2^R172^,\                                                                        
  or Vector (Figure 2B)                                                                         
  -----------------------------------------------------------------------------------------------------------------

^1^ 7 samples per group will be used based on the planned comparisons making the power at least 80%.

### Test family {#s2-4-4}

-   2 tailed *t* test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.0125

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib4]).

#### Figure 2A (NADPH production) values {#s34}

  Group 1   Group 2       Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- ------------- ----------------- ---------------- --------------------- ---------------------
  Vector    IDH2^WT^      3.05134           98.8%^1^         7^1^                  7^1^
  Vector    IDH2^R172K^   2.12463^2^        80.0%^2^         7                     7

^1^ 7 samples per group will be used based on the Vector vs IDH2^R172K^ NADP^+^ planned comparison making the power 98.8%.

^2^ A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.49386.

#### Figure 2B (NADP^+^ production) values {#s35}

  Group 1   Group 2       Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- ------------- ----------------- ---------------- --------------------- ---------------------
  Vector    IDH2^WT^      2.12463^1^        80.0%^1^         7                     7
  Vector    IDH2^R172K^   2.21471           89.3%            7                     7

^1^ A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.47369.

### Test family {#s2-4-5}

-   Due to the large variance, these parametric tests are only used for comparison purposes. To ensure an adequate sample size is used, the number is based on the non-parametric tests listed above.

-   2 tailed *t* test, difference between two independent means, Bonferroni's correction: alpha error = 0.0125

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib4]).

#### Figure 2A (NADPH production) values {#s37}

  Group 1   Group 2       Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- ------------- ----------------- ---------------- --------------------- ---------------------
  Vector    IDH2^WT^      3.05134           99.2%^1^         7^1^                  7^1^
  Vector    IDH2^R172K^   2.03^2^           80.0%^2^         7                     7

^1^Seven samples per group will be used based on the Vector vs IDH2^R172K^ NADP^+^ planned comparison making the power 98.8%.

^2^ A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.33972.

#### Figure 2B (NADP^+^ production) values {#s38}

  Group 1   Group 2       Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- ------------- ----------------- ---------------- --------------------- ---------------------
  Vector    IDH2^WT^      2.05829^1^        80.0%^1^         7                     7
  Vector    IDH2^R172K^   2.03              90.4%            7                     7

^1^ A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.51213.

Protocol 2: Figure 3D {#s2-5}
---------------------

Summary of original data

-   Note: data estimated from published graphs

  Sample        Mean intracellular 2-HG/glutamate   Assumed N
  ------------- ----------------------------------- -----------
  Vector        0.0105                              3
  IDH2^WT^      0.0102                              3
  IDH2^R172K^   1.2                                 3

### Test family {#s2-5-1}

-   One way ANOVA followed by Bonferroni corrected planed comparisons:Power calculations:Vector vs. IDH2^R172K^IDH2^WT^ vs. IDH2^R172K^Sensitivity CalculationsVector vs. IDH2^WT^

### Power calculations {#s2-5-2}

-   Power calculations were performed using GraphPad PRISM v6 and G\*Power (version 3.1.7) ([@bib4])

-   Because the data did not display variance, we have performed power calculations with a range of variances and an assumed N of 3 per group.

-   2% variance

  ANOVA; α=0.05                                                                                    
  -------------------------------------------------- -------------- --------------- -------------- ---------
  F(2,6)                                             Partial eta2   Effect size f   Power          Total N
  7370                                               0.999593       49.55807        \>99.99%       6\*
  Power calculations; α=0.05                                                                       
  Group 1                                            Group 2        Effect size d   Power          N/group
  Vector                                             IDH2^WT^       70.10710478     \>99.99%       2\*
  IDH2^WT^                                           IDH2^R172K^    70.08927663     \>99.99%       2\*
  Sensitivity Calculations; α=0.05, powered to 80%                                                 
  Group 1                                            Group 2        Effect size d   Detectable d   N/group
  Vector                                             IDH2^R172K^    1.449123183     0.2774844      3

\*With a minimum of 3 per group (9 total), achieved power is \>99.99%.

-   15% variance

  ANOVA; α=0.05                                                                                    
  -------------------------------------------------- -------------- --------------- -------------- ---------
  F(2,6)                                             Partial eta2   Effect size f   Power          Total N
  131                                                0.977612       6.608085        99.99%         6\*
  Power calculations; α=0.05                                                                       
  Group 1                                            Group 2        Effect size d   Power          N/group
  Vector                                             IDH2^WT^       9.347613971     98.65%         2\*
  IDH2^WT^                                           IDH2^R172K^    9.345236884     98.65%         2\*
  Sensitivity Calculations; α=0.05, powered to 80%                                                 
  Group 1                                            Group 2        Effect size d   Detectable d   N/group
  Vector                                             IDH2^R172K^    0.193216424     0.0539826      3

\*With a minimum of 3 per group (9 total), achieved power is \>99.99%.

-   28% variance

  ANOVA; α=0.05                                                                                    
  -------------------------------------------------- -------------- --------------- -------------- ---------
  F(2,6)                                             Partial eta2   Effect size f   Power          Total N
  37.60                                              0.926108       3.540235        98.61%         6\*
  Power calculations; α=0.05                                                                       
  Group 1                                            Group 2        Effect size d   Power          N/group
  Vector                                             IDH2^WT^       5.007650342     99.28%         3
  IDH2^WT^                                           IDH2^R172K^    5.006376902     99.28%         3
  Sensitivity Calculations; α=0.05, powered to 80%                                                 
  Group 1                                            Group 2        Effect size d   Detectable d   N/group
  Vector                                             IDH2^R172K^    0.103508799     0.0511419      3

\*With a minimum of 3 per group (9 total), achieved power is 99.99%.

-   40% variance

  ANOVA; α=0.05                                                                                    
  -------------------------------------------------- -------------- --------------- -------------- ---------
  F(2,6)                                             Partial eta2   Effect size f   Power          Total N
  18.43                                              0.860009       2.478571        85.73%         6\*
  Power calculations; α=0.05                                                                       
  Group 1                                            Group 2        Effect size d   Power          N/group
  Vector                                             IDH2^WT^       3.505355239     88.73%         3
  IDH2^WT^                                           IDH2R172K      4.205285771     96.37%         3
  Sensitivity Calculations; α=0.05, powered to 80%                                                 
  Group 1                                            Group 2        Effect size d   Detectable d   N/group
  Vector                                             IDH2^R172K^    0.072456159     0.0505594      3

\*With a minimum of 3 per group (9 total), achieved power is 99.92%.

-   In order to produce quantitative replication data, we will run the experiment three times. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

-   Note: Simulation analysis was also conducted using randomly generated values based on the SD and variance desired. These data are comparable to what is seen above when using a parametric model approach. Also there may be a need to appropriately transform these data based on the scale of Figure 3D, and we have assumed that this is one representative sample and not averages of all the data showing no variance. This simulation will be loaded to the OSF (<https://osf.io/8l4ea/>).

Protocol 3: Figure 5C {#s2-6}
---------------------

### Summary of original data {#s2-6-1}

-   Note: data estimated from published graphs and log transformed. Data includes IDH^WT^ (no mutations in *IDH1* or *IDH2*), IDH1^R132C/G^, IDH2^Mutant^ (IDH2^R172K^ and IDH2^R140Q^)

  Sample              2HG/glutamate   log(2HG/glut)
  ------------------- --------------- ---------------
  IDH^WT^(Constant)   0.01            -4.605
  IDH1^Mutant^        0.600           -0.511
  IDH1^Mutant^        1.200           0.182
  IDH1^Mutant^        1.600           0.470
  IDH1^Mutant^        1.800           0.588
  IDH1^Mutant^        3.000           1.099
  IDH1^Mutant^        0.600           -0.511
  IDH2^Mutant^        0.140           -1.966
  IDH2^Mutant^        0.160           -1.832
  IDH2^Mutant^        0.290           -1.237
  IDH2^Mutant^        0.300           -1.204
  IDH2^Mutant^        0.310           -1.171
  IDH2^Mutant^        0.470           -0.755
  IDH2^Mutant^        0.590           -0.528
  IDH2^Mutant^        0.310           -1.171

### Test family {#s2-6-2}

-   One sample t-test comparing Constant and mutant *IDH* groups:Constant vs. *IDH1^R132C/G^*Constant vs. *IDH2^mutant^* (grouped)Constant vs. *IDH1/2^mutant ^*(grouped)

### Power calculations {#s2-6-3}

Power calculations were performed using R software version 3.2.2 and G\*Power (version 3.1.7) ([@bib4]). Bonferroni corrected one-sample *t*-tests compared to. 01 (threshed as reported by original authors).

  Constant   Group            Effect size *d*   A priori power   Group sample size
  ---------- ---------------- ----------------- ---------------- -------------------
  0.01       IDH1^R132C/G^    8.404             99.99%           4
  0.01       IDH2^Mutant^     6.746             99.99%           4
  0.01       IDH1/2^Mutant^   4.361             99.99%           4

-   Because of the inherent complications that can occur when using primary patient cell lines, we have adjusted our sample size to four samples/group even though we achieve \>90% power when using three samples/group.

The Reproducibility Project: Cancer Biology core team would like to thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank Kermit L. Carraway III, Kacey Vandervorst, and Jason Hatakeyama from the Department of Biochemistry and Molecular Medicine at UC Davis and the UC Davis Comprehensive Cancer Center for methods consultation. The following companies generously donated reagents to the Reproducibility Project: Cancer Biology; American Type and Tissue Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Jessica Tyler as Reviewing Editor and Vivek Malhotra as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you perform your study, and then submit your revised submission once the experiments are complete.

Summary:

The submitted report plan will replicate the results of the key experiments in Ward et al., 2010, using three protocols to replicate the experiments. Power calculations and confirmatory analysis plans are described. In general the authors have done a great job, and the proposed analyses are appropriate and accurate, but we have the following suggestions:

Essential revisions:

1\) In the confirmatory analysis plan of the Protocols 2 and 3, One-way ANOVA is followed by planned comparisons using Fisher\'s LSD and in the corresponding power calcualtions for the t-tests of Protocol 2, a 0.05 α error is used. Fisher\'s LSD however does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. If that is the same statistical analysis method that was used in the original paper, we would like you to do it, but we would also like you to perform a Bonferroni correction (α = 0.025), as this is superior.

Anthony J. Hayter. The maximum familywise error rate of fisher\'s least significant difference test. Journal of the American Statistical Association, 81(396):

1000-1004, 1986. doi: 10.1080/01621459.1986.10478364.

2\) Rather than combining the *IDH1* mutant and *IDH2* mutant patient samples into a single group (table after "Power calculations" in subheading "Protocol 3: Figure 5C"), it will be useful to also consider them as two separate groups in addition to *IDH1*+*IDH2*, as the difference in subcellular localization may lead to differences in D2HG abundance, and it would be worth knowing if there are differences in *IDH1* mutants vs. *IDH2* mutants, in addition to control comparisons. This would obviously change the statistical comparison needed to analyze the data.

For your interest, we wanted to communicate to you some insightful suggestions that the reviewers had to improve the impact of the findings of the analyses beyond the original study. We appreciate that that is not the intent of the reproduction goal of the Registered report, but we include those ideas here as they may be worthy of your consideration for increasing the impact of this study and/or your future work:

1\) It may be useful to include *IDH2 ^R140Q^* mutants in the cell based studies, as it is likely that some AML patient samples will harbor that specific mutation.

2\) An estimation of non-*IDH1,2*-formed 2-HG levels would be useful.

3\) Distinction between the R and S chiral forms of 2-HG would be useful.

4\) Concerning the Protocol 1, i.e. replication of the Figure 2 experiments from the original article, this test represents biochemical assays of somewhat \"reconstituted\" WT or mutant *IDH2* forms and is of the appropriate design. The design could be improved only by a few variations of the overexpressed *IDH2*, either WT or mutant, to better correlate the possible variations due to the different levels of expression between WT or mutant. The statistics to be performed is sufficient to encompass the quality of the data and results even if the overexpression strength is not varied.

5\) Concerning the Protocol 2, i.e. replication of the Figure 3 experiments there is a problem whether \"mere reproducibility\" is tested or whether a scientific design of this experiment is to be scrutinized. In the former case, assessment is similar as for the Protocol 1. In the latter case however, the experimental design cannot exclude the possibility that WT enzyme does not form 2-HG, since conditions for this counter-Krebs cycle direction of reaction are not set up in the experimental design. Actually such conditions were set up if 2-HG was assayed in experiments similar to those in protocol 1, but long-term - where both directions of reaction are assayed in parallel. The Protocol 2 also cannot rule out the possibility, that mutant enzyme occurring under conditions leading to the forward-Krebs cycle direction is as inefficient in synthesizing 2-HG as the WT.

6\) Concerning the Protocol 3, i.e. replication of the Figure 5 experiments analyzing the AML patient samples the precise error-free identification of mutations is the key to good reproducibility. Since this effort should rather mimic a clinical study, you should do the best to maximize the quality of these replication analyses and should substantially increase the number of samples per group. The suggested 4 samples per group are fulfilling a power of 80%, which however only represents a single repeat of the figure from the original publication but not validation of the possible diagnostic testing.

7\) It would potentially be more beneficial to also focus on other aspects related to D or L2HG and *IDHs* such as the effects on epigenetics and the therapeutic potential of targeting 2HG-mediated epigenetic alterations.

10.7554/eLife.12626.003

Author response

*1) In the confirmatory analysis plan of the Protocols 2 and 3, One-way ANOVA is followed by planned comparisons using Fisher\'s LSD and in the corresponding power calcualtions for the t-tests of Protocol 2, a 0.05 α error is used. Fisher\'s LSD however does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. If that is the same statistical analysis method that was used in the original paper, we would like you to do it, but we would also like you to perform a Bonferroni correction (α = 0.025), as this is superior.*

*Anthony J. Hayter. The maximum familywise error rate of fisher\'s least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364.*

With regard to Protocol 2, we agree with the reviewers' comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter to control for the MFWER, however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 200 (Chapter 5) and Cohen, 2001 (Chapter 12).

References:

Levin, J.R., Serline, R.C., & Seaman M.A. (1994). A controlled, powerful multiple-comparison strategy for several situations. Psychological Bulletin, 115, 153-159.

Maxwell, S.E. & Delaney, H.D. (2004). Designing experiments and analyzing data: a model comparison perspecitive. Lawrence Erlbaum Associates, Mahwah, N.J., 2nd edition.

Cohen, B.H. (2001). Explaining psychological statistics. John Wiley and Sons, New York, 2nd edition.

As for Protocol 3, we have clarified this section. We will perform 3 one sample t-tests compared to the constant (a threshold of 0.01(WT) as defined by Ward et al.). The comparisons will be constant vs. *IDH1* mutant, constant vs. *IDH2* mutant, and constant vs. *IDH1/2* pooled mutants.

2\) Rather than combining the IDH1 mutant and IDH2 mutant patient samples into a single group (table after "Power calculations" in subheading "Protocol 3: Figure 5C"), it will be useful to also consider them as two separate groups in addition to IDH1+IDH2, as the difference in subcellular localization may lead to differences in D2HG abundance, and it would be worth knowing if there are differences in IDH1 mutants vs. IDH2 mutants, in addition to control comparisons. This would obviously change the statistical comparison needed to analyze the data.

We apologize for the confusion here. There was a typo in the table. Only *IDH2* mutants will be combined for all analyses because of the likely low percentage of samples that will harbor the *IDH2^R172^* allele. Further we plan on combining all IDH mutation and compare them to WT. With regard to the *IDH1* vs. *IDH2* mutants, because the Ward et al. paper never made these comparisons this analysis would be outside of the scope of the proposal. However, all data from this project will be made publically available to allow for further exploratory analysis such as this.

For your interest, we wanted to communicate to you some insightful suggestions that the reviewers had to improve the impact of the findings of the analyses beyond the original study. We appreciate that that is not the intent of the reproduction goal of the Registered report, but we include those ideas here as they may be worthy of your consideration for increasing the impact of this study and/or your future work:

*1) It may be useful to include IDH2 ^R140Q^ mutants in the cell based studies, as it is likely that some AML patient samples will harbor that specific mutation.*

We apologize if this was not made clear initially. Any *IDH2 ^R140Q^* mutants that are identified in our sampling will be included in the replication of original Figure 5C. An addition has been made to the Sampling section of Protocol 3 to clarify this.

*2) An estimation of non-IDH1,2-formed 2-HG levels would be useful.*

We agree with the reviewers that this would be an interesting investigation. While outside of the scope of this specific project, all data from GC-MS will be made publically available to allow for further exploratory analysis.

*3) Distinction between the R and S chiral forms of 2-HG would be useful.*

We agree with the reviewers that this would be an interesting investigation. While outside of the scope of this specific project, all data from GC-MS will be made publically available to allow for further exploratory analysis.

*4) Concerning the Protocol 1, i.e. replication of the Figure 2 experiments from the original article, this test represents a biochemical assays of somewhat \"reconstituted\" WT or mutant IDH2 forms and is of the appropriate design. The design could be improved only by a few variations of the overexpressed IDH2, either WT or mutant, to better correlate the possible variations due to the different levels of expression between WT or mutant. The statistics to be performed is sufficient to encompass the quality of the data and results even if the overexpression strength is not varied.*

We agree that investigating the dose dependent impact of *IDH* overexpression on NADP-NADPH and NADPH-NADP would be interesting, however it is outside of the scope of this project as the original authors did not perform this experiment.

*5) Concerning the Protocol 2, i.e. replication of the Figure 3 experiments there is a problem whether \"mere reproducibility\" is tested or whether a scientific design of this experiment is to be scrutinized. In the former case, assessment is similar as for the Protocol 1. In the latter case however, the experimental design cannot exclude the possibility that WT enzyme does not form 2-HG, since conditions for this counter-Krebs cycle direction of reaction are not set up in the experimental design. Actually such conditions were set up if 2-HG was assayed in experiments similar to those in protocol 1, but long-term - where both directions of reaction are assayed in parallel. The Protocol 2 also cannot rule out the possibility, that mutant enzyme occurring under conditions leading to the forward-Krebs cycle direction is as inefficient in synthesizing 2-HG as the WT.*

We agree with the reviewers that this could be the case and we have done our best to design the experiments detailed in this protocol to be a "direct" replication. Study design is always an aspect to be investigated but like the other analyses, all data will be made public so that future analyses can take into account these aspects.

*6) Concerning the Protocol 3, i.e. replication of the Figure 5 experiments analyzing the AML patient samples the precise error-free identification of mutations is the key to good reproducibility. Since this effort should rather mimic a clinical study, you should do the best to maximize the quality of these replication analyses and should substantially increase the number of samples per group. The suggested 4 samples per group are fulfilling a power of 80%, which however only represents a single repeat of the figure from the original publication but not validation of the possible diagnostic testing.*

We understand the reviewers' concerns about identification of mutational status and believe this has essential clinical implications. Here, our replication attempt is meant specifically to address the difference in 2HG/glutamate in *IDH* mutants vs. controls as reported in the original paper and not necessarily to investigate the precision of using 2HG/glutamate to identify *IDH* mutations, which we agree would require a larger sample size. The cell lines that we are obtaining are Roswell Park Cancer Institute and mutations have been confirmed multiple times on different platforms. Based on our power analyses, 4 samples should achieve 99% power to detect the published differences in 2HG/glutamate between WT and mutant *IDH*, as the effect size is quite large. Please keep in mind that the scale of Figure 5C is logarithmic.

7\) It would potentially be more beneficial to also focus on other aspects related to D or L2HG and IDHs such as the effects on epigenetics and the therapeutic potential of targeting 2HG-mediated epigenetic alterations.

We agree that these are interesting avenues of investigation, however, they are outside of the scope of this project.
